Open Sat 9:00am : 01582 842096
FREE DELIVERY on most orders over £29
VioVet Insurance
  • Equip R (Rotavirus) » 10 x 1 Dose £489.52
  • IE-T Plus » 10 x 1 Dose £218.13
  • IE Plus » 10 x 1 Dose £160.90
  • T » 10 x 1 Dose £86.39

Selection of 4 products from

£86.39 to £489.52

Description

Duvaxyn Injections can be purchased from VioVet at fantastic prices. With free delivery of most orders over £29 and a wide range of products available, you can buy with confidence from VioVet!

Duvaxyn IE Plus

Presentation

Equine influenza vaccine (inactivated) in suspension for injection

Active Substances: Per 1.0ml dose

Inactivated equine influenza virus, strains:

A/equi-1/Prague/56 15- 18 μg HA*

A/equi-2/Suffolk/89 (European type) 15 - 18 μg HA*

A/equi-2/Newmarket/1/93 (American type) 15 - 18 μg HA*

*Haemagglutinin

Adjuvant: Per 1.0ml dose

Carbopol 934P 4mg

Uses

For the active immunisation of horses and ponies to reduce clinical signs of respiratory disease and viral shedding caused by equine influenza viruses of H7N7 and H3N8 types (European and American strains) as demonstrated by serology and challenge infection using the following strains;

- A/equi-2/South Africa/4/03 (a Clade 1 strain of the Florida sublineage)

- A/equi-2/Richmond/1/07 (a Clade 2 strain of the Florida sublineage)

Protective antibody titres against the listed equine influenza virus strains have been shown to be present within two weeks of completion of the second dose of the primary vaccination course and protection has been demonstrated against challenge with virulent isolates of the listed equine influenza virus strains.

Following administration of the second dose of the primary vaccination course, protective antibody titres against the listed equine influenza strains last at least 6 months. After completion of the 3 dose primary vaccination course and for subsequent booster vaccinations, protective antibody titres against the listed equine influenza strains last at least 1 year.

Dosage and administration

One 1.0 ml dose per horse to be administered by deep intramuscular injection. Shake well before use.

Primary vaccination

A single dose of Duvaxyn IE Plus should be administered from the age of 5 months followed by a second dose of Duvaxyn IE Plus after an interval of 4–6 weeks and a third dose 6 months later.

Primary vaccination of foals born to mares highly immunised against equine influenza (i.e. vaccinated two or more times a year or within the last trimester of pregnancy) should be delayed until the age of 6 months, as such foals may have high levels of maternally-derived antibody against equine influenza virus that could interfere with successful immunisation.

In cases of increased risk of equine influenza in the young foal, especially when colostrum intake has been inadequate, an additional vaccination may be given from three months of age. Such foals should be shown to have no or very low titres of IgG using a suitable test before proceeding with early vaccination.

The full primary course of vaccination should still be given from five months of age.

Booster vaccination

Administer a single dose of vaccine annually.

In enzootic or epizootic situations, especially where the causative strain of equine influenza has not been identified, young horses in a yard or crowded situation may be particularly at risk and an additional 6 month booster with Duvaxyn IE Plus may be given in order to further enhance the immune response prior to the commencement of the annual booster programme.

It is recommended that Duvaxyn IE Plus should not be used as a booster vaccine in horses previously vaccinated with another manufacturer's vaccine nor should another manufacturer's vaccine be used as a booster vaccine in horses previously vaccinated with Duvaxyn IE Plus unless the other manufacturer's vaccine comprises the same equine influenza strains as Duvaxyn IE Plus.

Contra-indications, warnings, etc

For Animal Treatment Only.

Do not vaccinate unhealthy animals.

It is recommended to vaccinate all horses on the premises according to the recommended schedule.

Maternally derived antibodies (MDA) can interfere with the development of active immunity. Please refer to dose and administration for advice on vaccination in the presence of MDA.

Duvaxyn IE Plus is safe for use in pregnant mares in the second and third trimester, which have been vaccinated against influenza before pregnancy.

Avoid stress in the animals around the time of vaccination.

Safety and efficacy data are available which demonstrate that this vaccine can be safely administered on the same day but not mixed with Duvaxyn EHV 1,4 and Duvaxyn T.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Operator warning

In the case of accidental self-injection/ingestion/spillage onto skin, seek medical advice immediately and show the package insert or label to the physician.

Adverse reactions

The occurence of adverse reactions after the first and second doses is low. After the third and subsequent doses, the incidence of adverse reactions, particularly local reactions, increases. In those cases where adverse reactions do occur, very commonly these reactions include visible swellings measuring less than 5 cm in diameter lasting for up to 1 day and mild, transient hyperthermia lasting up to 4 days. Common reactions include palpable, transient swellings and visible swellings measuring more than 5 cm in diameter which resolve within weeks and stiffness of the neck evident at between 2 to 4 days after vaccination. In rare occasions, abscessation may be observed. No information on microscopic features of the injection site reactions is available.

Hypersensitivity reactions to the vaccine may occur. In the event of an allergic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously (e.g. dexamethasone sodium phosphate), adrenaline intramuscularly or antihistamine intramuscularly.

Withdrawal period

Zero days.

Pharmaceutical precautions

Store and transport refrigerated (2°C to 8°C). Do not freeze. Protect from light. Keep out of the reach and sight of children.

Do not use after the expiry date stated on the label.

Do not mix with any other veterinary medicinal product.

Legal category

POM-V

Packaging Quantities

2, 10 or 50 × 1 dose vials. Not all pack sizes may be marketed.

Further information

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing authorisation number

Vm 00006/4125

GTIN (Global Trade Item No)

Duvaxyn IE Plus

5014602853495

Duvaxyn IE-T Plus

Presentation

Combined equine influenza vaccine (inactivated) and tetanus vaccine for veterinary use.

Active Substances: Per 1.5ml dose

Inactivated equine influenza virus, strains:

A/equi-1/Prague/56 15 - 18 μg HA*

A/equi-2/Suffolk/89 (European type) 15 - 18 μg HA*

A/equi-2/Newmarket/1/93 (American type) 15 - 18 μg HA*

Tetanus Toxoid 18 Lf (RP≥1,0)**

*Haemagglutinin

**Mean potency relative to a reference vaccine of known potency: ≥150 IU/dose

Adjuvants: Per 1.5ml dose

Carbopol 934P 4mg

Aluminium hydroxide 2.2mg

Uses

For the active immunisation of horses and ponies to reduce clinical signs of respiratory disease and viral shedding caused by equine influenza viruses of H7N7 and H3N8 types (European and American strains) as demonstrated by serology and challenge infection using the following strains;

- A/equi-2/South Africa/4/03 (a Clade 1 strain of the Florida sublineage)

- A/equi-2/Richmond/1/07 (a Clade 2 strain of the Florida sublineage)

For the active immunisation of horses and ponies against Clostridium tetani toxin (Tetanus).

Protective antibody titres against the listed equine influenza virus strains and protective antitoxin antibody titres have been shown to be present within two weeks of completion of the second dose of the primary vaccination course and protection has been demonstrated against challenge with virulent isolates of the listed equine influenza virus strains.

Following administration of the second dose of the primary vaccination course, protective antibody titres against the listed equine influenza strains and protective antitoxin antibody titres last at least 6 months. After completion of the 3 dose primary vaccination course and for subsequent booster vaccinations, protective antibody titres against the listed equine influenza strains last at least 1 year and against tetanus last at least 2 years.

Dosage and administration

One 1.5ml dose per horse to be administered by deep intramuscular injection. Shake well before use.

Vaccination Schedule:

Primary vaccination

A single dose of Duvaxyn IE‑T Plus should be administered from the age of 5 months followed by a second dose of Duvaxyn IE‑T Plus after an interval of 4–6 weeks and a third dose 6 months later.

Primary vaccination of foals born to mares highly immunised against equine influenza or tetanus (i.e. vaccinated two or more times a year or within the last trimester of pregnancy) should be delayed until the age of 6 months, as such foals may have high levels of maternally-derived antibody against equine influenza virus and tetanus toxoid that could interfere with successful immunisation.

In cases of increased risk of equine influenza or tetanus in the young foal, especially when colostrum intake has been inadequate, an additional vaccination may be given from three months of age. Such foals should be shown to have no or very low titres of IgG using a suitable test before proceeding with early vaccination.

The full primary course of vaccination should still be given from five months of age.

Booster vaccination

Administer a single dose of vaccine annually, beginning with Duvaxyn IE Plus and alternating thereafter with Duvaxyn IE-T Plus.

In enzootic or epizootic situations, especially where the causative strain of equine influenza has not been identified, young horses in a yard or crowded situation may be particularly at risk and an additional 6 month booster with Duvaxyn IE Plus may be given in order to further enhance the immune response prior to the commencement of the annual booster programme.

It is recommended that Duvaxyn IE-T Plus should not be used as a booster vaccine in horses previously vaccinated with another manufacturer's vaccine nor should another manufacturer's vaccine be used as a booster vaccine in horses previously vaccinated with Duvaxyn IE-T Plus unless the other manufacturer's vaccine comprises the same equine influenza strains as Duvaxyn IE-T Plus.

Contra-indications, warnings, etc

For Animal Treatment Only.

Do not vaccinate unhealthy animals.

It is recommended to vaccinate all horses on the premises according to the recommended schedule.

Maternally derived antibodies (MDA) can interfere with the development of active immunity. Please refer to dose and administration for advice on vaccination in the presence of MDA.

Animals that have received tetanus antiserum at a therapeutic dosage should not be vaccinated until an interval of at least 4 weeks has elapsed.

Safe for use in pregnant mares in second to third trimester which have been vaccinated against both influenza and tetanus before pregnancy.

Avoid stress in the animals around the time of vaccination.

Safety and efficacy data are available which demonstrates that this vaccine can be administered on the same day but not mixed with Duvaxyn EHV 1,4. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Operator Warning:

In the case of accidental self-injection/ingestion/spillage onto skin, seek medical advice immediately and show the package insert or label to the physician.

Adverse reactions

The occurrence of adverse reactions after the first and second doses is low. After the third and subsequent doses, the incidence of adverse reactions, particularly local reactions, increases. In those cases where adverse reactions do occur, very commonly these reactions include visible swellings measuring less than 5 cm in diameter lasting for up to 1 day and mild, transient hyperthermia lasting up to 4 days. Common reactions include palpable, transient swellings and visible swellings measuring more than 5cm in diameter which resolve within weeks and stiffness of the neck evident at between 2 to 4 days after vaccination. In rare occasions, abscessation may be observed. No information on microscopic features of the injection site reactions is available.

Hypersensitivity reactions to the vaccine may occur. In the event of an allergic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously (e.g. dexamethasone sodium phosphate), adrenaline intramuscularly or antihistamine intramuscularly.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary practitioner.

Withdrawal period

Zero days.

Pharmaceutical precautions

Store and transport refrigerated (2°C - 8°C). Do not freeze. Protect from light. Keep out of the reach and sight of children. Do not use after the expiry date stated on the label.

Legal category

POM-V

Packaging Quantities

2, 10, 50 x 1 dose vials.

Not all pack sizes may be marketed.

Further information

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing authorisation number

Vm 00006/4127

GTIN (Global Trade Item No)

Duvaxyn IE-T Plus

5014602853488

Duvaxyn T

Presentation

Purified Tetanus toxoid, ≥30 IU* per 1ml dose.

*Mean potency determined by enzyme linked immunosorbant assay (ELISA) compared to a reference antiserum. Ph Eur. 0697

Uses

For the active immunisation of horses and ponies against tetanus. Protective antitoxin antibody titres are detected within two weeks of the second vaccination and last for 1 year. After the third vaccination and subsequent biannual booster vaccinations, protective titres last two years.

Dosage and administration

One 1.0ml dose per horse to be administered by deep intramuscular injection.

Vaccination Schedule

Primary Course:

A single dose of Duvaxyn T should be administered from 3 months of age followed by a second injection of Duvaxyn T after an interval of 4-6 weeks and a third injection one year after that.

Primary vaccination of foals born to mares highly immunised against tetanus (i.e. vaccinated two or more times a year or within the last trimester of pregnancy) should be delayed until the age of 6 months, as such foals may have high levels of maternally derived antibody against tetanus toxoid that could interfere with successful immunisation.

Booster Immunity:

Booster vaccinations should be administered at two year intervals.

Correct Administration:

Syringes and needles should not have been sterilised chemically or be above ambient temperature.

Contra-indications, warnings, etc

Do not use in unhealthy animals.

Duvaxyn T may only be used in pregnant or lactating mares which have been given a primary vaccination course prior to pregnancy. However, the risks connected with any treatment of a pregnant animal are undiminished.

No information is available on the safety and efficacy of the concurrent use of this vaccine with any other except Duvaxyn IE Plus or Duvaxyn EHV 1,4. It is therefore recommended that no other vaccines than these should be administered within 14 days before or after vaccination with this product.

Do not mix with any other vaccine or immunological product.

Adverse reactions

Following administration of Duvaxyn T, a small, palpable injection-site reaction may result in approximately 2% of vaccinated animals. No information on microscopic features of the injection site reaction is available. Transient elevation of body temperature may be seen within a few days of vaccination in approximately 2% of vaccinated animals. While extremely rare, hypersensitivity reactions to the vaccine may occur. In the event of an allergic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously (e.g. dexamethasone sodium phosphate), adrenaline intramuscularly or antihistamine intramuscularly.

Special warnings

The skin at the site chosen for injection should not be disinfected prior to vaccination using chemical disinfectants.

Maternally derived antibody (MDA) can interfere with the development of active immunity. Where it is likely that recent field infection or vaccination of the dam has stimulated a high antibody titre and consequently a high level of MDA, the timing of the vaccination programme should be planned accordingly.

In any animal population there will be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the animal's ability to respond. Immune competence can be influenced by genetic factors, intercurrent infection, age, nutritional status, concurrent drug therapy, stress, etc.

Animals that have received the corresponding antiserum at a therapeutic dosage, or immunosuppressive drugs (e.g. glucocorticoids) should not be vaccinated until an interval of at least 4 weeks has elapsed.

Special precautions for use in animals

Avoid stress in the animals around the time of vaccination.

Operator warning

In the case of accidental self-injection/ingestion/spillage onto skin, seek medical advice immediately and show the package insert or label to the physician.

Withdrawal Period

Zero days

Pharmaceutical precautions

Store and transport at +2°C to +8°C. Do not freeze. Protect from light.

For Animal Treatment Only

Keep out of reach and sight of children.

Use entire contents when first opened.

Legal category

POM-V

Packaging Quantities

Packs of 2 and 10 single dose vials.

Not all pack sizes may be marketed.

Further information

Disposal:

Any unused veterinary medicinal products or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing authorisation number

Vm 00006/4124

GTIN (Global Trade Item No)

Duvaxyn T

5014602853471

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Questions & Answers for Duvaxyn Injections

There are currently no questions for Duvaxyn Injections - be the first to ask one!

Ask A Question